PillRx only · Injection, Powder, Lyophilized, For Solution · Intravenous
Piperacillin And Tazobactam
Piperacillin Sodium + Tazobactam Sodium
5 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US20 NDCs
5 active makers
5 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 4 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$3.493
Latest avg · Jan 21, 2026
+2%
Since Dec 17, 2025
5
Active US suppliers
71%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
2.4K
Rx · 2026 Q1
12K
Units dispensed
-10%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it5 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Fresenius Kabi USA, LLC | unknown | 10 | SUPPLYING |
| Sandoz Inc | unknown | 7 | SUPPLYING |
| Hospira, Inc. | unknown | 5 | SUPPLYING |
| Apotex Corp. | unknown | 1 | SUPPLYING |
| Shandong Anxin Pharmaceutical Co., Ltd. | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Jan 20, 2026RESOLVEDShortage resolved: Piperacillin and Tazobactam Injection (Fresenius Kabi USA, LLC)
Piperacillin and Tazobactam Injection — reported in shortage by Fresenius Kabi USA, LLC. Therapeutic category: Anti-Infective.
- Jan 20, 2026SHORTAGEDrug shortage: Piperacillin and Tazobactam Injection (Fresenius Kabi USA, LLC)
Piperacillin and Tazobactam Injection — reported in shortage by Fresenius Kabi USA, LLC. Therapeutic category: Anti-Infective.